Adma Biologics: Up on transfer of drug licenses from Biotest Pharma

ADMA Biologics

08/07/2019 14:24

** Drug developer's shares  ADMA.O  rise 4% to $3.72
premarket  
    ** U.S. FDA informs co that licenses for Bivigam and Nabi-HB
have been transferred from Biotest Pharma to ADMA  urn:newsml:reuters.com:*:nGNX9fFJJB
    ** License transfer completes the final remaining regulatory
item from the ADMA's buyout of Biotest's therapy business unit,
says ADMA
    ** Bivigam is used to treat a a condition that compromises
the body's ability to fight infections and Nabi-HB helps prevent
Hepatitis B infection after a recent exposure to the virus
    ** Up to Friday's close, stock had risen 50% YTD

 (Reporting by Saumya Sibi Joseph in Bengaluru)
 ((Reuters Messaging:
saumya.joseph.thomsonreuters.com@reuters.net))